EGFR and breast cancer: The antiproliferative activities of LA and OC against BC cells were compared with a diverse panel of chemotherapeutic and targeted therapeutic drugs, including the microtubule depolymerization disruptor paclitaxel (PTX), the first-generation EGFR inhibitor gefitinib (GFT), the selective estrogen receptor modulator tamoxifen (TAM), the estrogen receptor degrader fulvestrant (FUL), in addition to the standard selective SMYD2 inhibitor BAY-598.